The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Aug 31, 2026
Snapshot (as of Aug 31, 2026): Takeda Pharmaceutical Company Limited (TKPHF) pays a $200.00 annual dividend ($16.67 monthly), yielding 3.47% at $36.62/share. Next ex-dividend date 2027-03-30. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.47%
Annual Dividend: $200.00 per share
Payout Ratio: 175.3% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2027-03-30
Dividend Frequency: monthly
Sector: Healthcare
Years of Dividend History: 14
Takeda Pharmaceutical Company Limited dividend investors are looking at a global biopharmaceutical company founded in 1781, with products spanning gastroenterology, oncology, rare diseases, and plasma-derived therapies — brands like Entyvio, Takhzyro, and Velcade anchor its commercial portfolio. The current yield stands at 3.47%, with trailing annual payments of $200.00 per share paid monthly. The next ex-dividend date is March 30, 2027. A beta of 0.088 points to very low price volatility, which suits income-focused investors who prioritize a steady share price over capital gains.
Takeda Pharmaceutical Company Limited pays out 175.3% of earnings as dividends, a payout ratio classified as high (above 75%). That figure sits well above 100%, meaning the company is paying more in dividends than it currently earns, a level that warrants scrutiny when evaluating Takeda Pharmaceutical Company Limited dividend safety. The company operates across multiple therapeutic areas with global commercial reach, but a payout ratio this elevated leaves little buffer if earnings come under pressure from pipeline setbacks or pricing headwinds.
Takeda Pharmaceutical Company Limited dividend history shows a CAGR of 1.4% per year from 2014 to 2025. Per-share payments moved from $1.71 to $1.9938 over that window (with 2026 a partial year). The largest annual increase in the window was 53.5% in 2025, but the history also contains at least one year-over-year decline exceeding 5%, so growth has been far from linear. At 1.4% annually, dividend growth is slow, and that limits the income upside for investors counting on rising payments over time.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +13.7% | $1.36 (2022) | $1.99 (2025) |
| 5-Year | +3.4% | $1.69 (2020) | $1.99 (2025) |
| 10-Year | +2.9% | $1.50 (2015) | $1.99 (2025) |
TKPHF stock fits income-focused investors who want low share-price volatility and a monthly payment from a globally diversified pharmaceutical business. The yield of 3.47% falls in the moderate (2-4%) range and sits below the 5-year average of 3.78%, so current buyers are getting slightly less income than the historical norm. The trade-off is real: a payout ratio of 175.3% means the dividend is not covered by current earnings, and growth over the past decade has averaged just 1.4% per year. What an investor gets is a low-beta, monthly-paying healthcare stock. What they accept is a payout structure that carries meaningful sustainability risk.
| Payment Date | Amount per Share |
|---|---|
| 2027-03-30 | $0.6368 |
| 2026-09-29 | $0.6368 |
| 2026-03-31 | $0.6286 |
| 2025-09-30 | $0.6758 |
| 2025-09-29 | $0.6690 |
| 2025-03-28 | $0.6490 |
| 2024-09-27 | $0.6770 |
| 2024-03-28 | $0.6220 |
| 2023-09-28 | $0.6290 |
| 2023-03-30 | $0.6780 |
| Year | Total Dividends |
|---|---|
| 2027 | $0.6368 |
| 2026 | $1.2654 |
| 2025 | $1.9938 |
| 2024 | $1.2990 |
| 2023 | $1.3070 |
Project income from TKPHF with the TKPHF dividend calculator or track your full portfolio with the dividend tracker.